Role of 5-aminosalicylic acid in ulcerative colitis management in 8 Asian territories: a physician survey

被引:0
|
作者
Limsrivilai, Julajak [1 ]
Lai, Allen Yu-hung [2 ]
Li, Silvia T. H. [4 ]
Abdullah, Murdani [5 ]
Ali, Raja Affendi Raja [6 ]
Aniwan, Satimai [7 ]
Bui, Hoang Huu [8 ]
Chou, Jen-Wei [9 ]
Hilmi, Ida Normiha [1 ,10 ]
Lim, Wee Chian [1 ,11 ]
Sollano, Jose [1 ,2 ,12 ]
Teo, Michelle Mui Hian [3 ]
Wei, Shu-Chen [1 ,13 ]
Leung, Wai Keung [14 ]
机构
[1] Mahidol Univ, Siriraj Hosp, Div Gastroenterol, Bangkok, Thailand
[2] Natl Taiwan Univ, Coll Publ Hlth, Global Hlth Program, Taipei, Taiwan
[3] AstraZeneca Ltd, Singapore, Singapore
[4] Univ Hong Kong, Li Ka Shing Fac Med, Ctr Safe Medicat Practice & Res, Dept Pharmacol & Pharm, Hong Kong, Peoples R China
[5] Univ Indonesia, Indonesian Med Educ & Res Inst, Div Gastroenterol Pancreatobiliary & Digest Endos, Div Gastroenterol Pancreatobiliary & Digest Endosc, Jakarta, Indonesia
[6] Sunway Univ, Sch Med & Life Sci, Kuala Lumpur, Malaysia
[7] Chulalongkorn Univ, Fac Med, Dept Med, Bangkok, Thailand
[8] Univ Med Ctr, Dept Gastroenterol, Ho Chi Minh City, Vietnam
[9] China Med Univ Hosp, Ctr Digest Med, Dept Internal Med, Taichung, Taiwan
[10] Univ Malaya, Dept Med, Div Gastroenterol & Hepatol, Kuala Lumpur, Malaysia
[11] Tan Tock Seng Hosp, Dept Gastroenterol & Hepatol, Singapore, Singapore
[12] Univ Santo Tomas, Fac Med & Surg, Manila, Philippines
[13] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan
[14] Univ Hong Kong, Li Ka Shing Fac Med, Sch Clin Med, Dept Med, Hong Kong, Peoples R China
关键词
Ulcerative colitis; Guidelines; 5-Aminosalicylates; Mesalamine; Inflammatory bowel diseases; GUIDELINES; DIAGNOSIS; TREAT; DELAY;
D O I
10.5217/ir.2024.00085
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Clinical guidelines typically endorse conventional therapies such as 5-aminosalicylic acid (5-ASA) as the mainstay of ulcerative colitis management. However, the degree of adoption and application of guideline recommendations by physicians within Asia remains unclear. This study aims to understand the prescribing patterns of 5-ASA and implementation of current guideline recommendations across Asian clinical practice. A physician survey was conducted among inflammatory bowel disease specialists in 8 Asian territories to understand practices and preferences in ulcerative colitis management, focusing on the use of 5-ASA and concordance with guideline recommendations. Survey findings were validated by country experts in diverse healthcare settings. Subgroup analyses stratified data by income levels and treatment reimbursement status. Ninety-eight valid responses were received from inflammatory bowel disease specialists or gastroenterologists among 8 economic entities. Significant differences were found in clinical practices and treatment preferences for ulcerative colitis management among different income-level and government-subsidy groups. Survey results are summarized in 8 findings that illustrate trends in 5-ASA use and guideline implementation across Asian territories. This study emphasizes socioeconomic factors that impact the adoption of guideline recommendations in real-world practice. Our findings indicate an eclectic approach to guideline implementation across Asia, based on resource availability and feasibility of treatment goals. (Intest Res, Published online )
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Significance of 5-Aminosalicylic Acid Intolerance in the Clinical Management of Ulcerative Colitis
    Mikami, Yohei
    Tsunoda, Junya
    Suzuki, Shohei
    Mizushima, Ichiro
    Kiyohara, Hiroki
    Kanai, Takanori
    DIGESTION, 2023, 104 (01) : 58 - 65
  • [2] 5-Aminosalicylic acid, a specific drug for ulcerative colitis
    Hauso, Oyvind
    Martinsen, Tom Christian
    Waldum, Helge
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2015, 50 (08) : 933 - 941
  • [3] Modern use of 5-aminosalicylic acid compounds for ulcerative colitis
    Le Berre, Catherine
    Roda, Giulia
    Protic, Marijana Nedeljkovic
    Danese, Silvio
    Peyrin-Biroulet, Laurent
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (04) : 363 - 378
  • [4] Predictors of persistence with 5-aminosalicylic acid therapy for ulcerative colitis
    Kane, S. V.
    Accortt, N. A.
    Magowan, S.
    Brixner, D.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 29 (08) : 855 - 862
  • [5] Perimyocarditis in a Patient with Ulcerative Colitis Treated with 5-Aminosalicylic Acid
    Lee, Hye Young
    Baek, Dong Hoon
    KOREAN JOURNAL OF GASTROENTEROLOGY, 2024, 83 (05): : 197 - 199
  • [6] Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis
    Wang, Yongjun
    Parker, Claire E.
    Bhanji, Tania
    Feagan, Brian G.
    MacDonald, John K.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (04):
  • [7] Treatment Adherence in Patients with Ulcerative Colitis Is Dependent on the Formulation of 5-Aminosalicylic Acid
    Nakagawa, Shoko
    Okaniwa, Noriko
    Mizuno, Mari
    Sugiyama, Tomoya
    Yamaguchi, Yoshiharu
    Tamura, Yasuhiro
    Izawa, Shinya
    Hijikata, Yasutaka
    Ebi, Masahide
    Ogasawara, Naotaka
    Funaki, Yasushi
    Sasaki, Makoto
    Kasugai, Kunio
    DIGESTION, 2019, 99 (02) : 133 - 139
  • [8] Synthesis and evaluation of a prodrug of 5-aminosalicylic acid for the treatment of ulcerative colitis
    Yan, Yan
    Ren, Fengling
    Wang, Pengchong
    Sun, Ying
    Xing, Jianfeng
    IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2019, 22 (12) : 1452 - 1461
  • [9] The Synergistic Effects of 5-Aminosalicylic Acid and Vorinostat in the Treatment of Ulcerative Colitis
    He, Long
    Wen, Shuting
    Zhong, Zhuotai
    Weng, Senhui
    Jiang, Qilong
    Mi, Hong
    Liu, Fengbin
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [10] Evaluating the effects of 5-aminosalicylic acid on tofacitinib treatment in ulcerative colitis
    Nishida, Yu
    Hosomi, Shuhei
    Fujimoto, Koji
    Kobayashi, Yumie
    Nakata, Rieko
    Maruyama, Hirotsugu
    Ominami, Masaki
    Nadatani, Yuji
    Fukunaga, Shusei
    Otani, Koji
    Tanaka, Fumio
    Fujiwara, Yasuhiro
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2025, 40 (01) : 108 - 114